Sun Pharma tumbles after US court halts Leqselvi launch

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

21 November 2024 00:00:00

Adani Ports

1114.70

(-13.53%)

Asian Paints

2429.20

(-2.17%)

Axis Bank

1139.10

(0.36%)

Bajaj Finance

6464.45

(-2.08%)

Bajaj Finserv

1568.65

(-1.65%)

Bharti Airtel

1524.95

(-0.07%)

HCL Technologi..

1836.10

(0.87%)

HDFC Bank

1741.95

(-0.02%)

Hind. Unilever

2383.25

(-1.14%)

ICICI Bank

1250.10

(0.11%)

IndusInd Bank

981.70

(-1.84%)

Infosys

1834.20

(0.47%)

ITC

457.15

(-2.18%)

JSW Steel

943.90

(-0.40%)

Kotak Mah. Ban..

1736.95

(0.60%)

Larsen & Toubr..

3482.50

(-0.66%)

M & M

2934.00

(-0.48%)

Maruti Suzuki

10861.80

(-0.97%)

Nestle India

2210.45

(-0.38%)

NTPC

356.10

(-2.73%)

Power Grid Cor..

325.80

(3.41%)

Reliance Indus..

1223.20

(-1.46%)

St Bk of India

780.85

(-2.64%)

Sun Pharma.Ind..

1777.65

(0.14%)

Tata Motors

773.70

(-1.24%)

Tata Steel

140.25

(0.57%)

TCS

4077.25

(0.94%)

Tech Mahindra

1701.30

(0.12%)

Titan Company

3178.70

(-1.21%)

UltraTech Cem.

10955.75

(1.68%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Sun Pharma tumbles after US court halts Leqselvi launch	Share Back
(04 Nov 2024)
Aa result of the court's decision, Sun Pharma has been temporarily barred from launching Leqselvi until a subsequent favorable court decision or until the expiry of patent in lawsuit, whichever is earlier, it added. Earlier on 1 August 2024, the pharma major had informed that it filed a motion seeking a preliminary injunction in a US court to prevent the launch of LEQSELVI. Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company. The company’s consolidated net profit jumped 27.97% to Rs 3,040.16 crore on 9.01% rise in revenue from operations to Rs 13,291.39 crore in Q2 FY25 over Q2 FY24.
Top